Intercept Pharmaceuticals has been gearing up for the potential launch of its nonalcoholic steatohepatitis (NASH) med, but now its wait looks a little longer. While the FDA was originally due to ...
Intercept Pharmaceuticals, the developer of liver disease drug Ocaliva, has agreed to be acquired by Italian Pharma company Alfasigma in an all-cash deal worth approximately $800 million. Intercept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback